Multispecific antibodies against CD40 and CD137

Patent metadata

Field	Value
Publication number	US-11440966-B2
Application number	US-202117345628-A
Country	US
Kind code	B2
Filing date	Jun 11, 2021
Priority date	Jul 14, 2016
Publication date	Sep 13, 2022
Grant date	Sep 13, 2022

Abstract

Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

First claim

The invention claimed is:

1. A multispecific antibody or a fragment thereof comprising a first heavy chain and a first light chain comprising a first antigen-binding region capable of binding to human CD40 and a second heavy chain and a second light chain comprising a second antigen-binding region capable of binding to human CD137
wherein the first antigen-binding region capable of binding to human CD40 comprises a first heavy chain variable (VH) region comprising an HCDR1 sequence comprising the amino acid sequence as set forth in SEQ ID NO: 1, an HCDR2 sequence comprising the amino acid sequence as set forth in SEQ ID NO: 2, and an HCDR3 sequence comprising the amino acid sequence as set forth in SEQ ID NO: 3, and a first light chain variable (VL) region comprising a LCDR1 sequence comprising the amino acid sequence as set forth in SEQ ID NO: 4, a LCDR2 sequence comprising the amino acid sequence YTS, and a LCDR3 sequence comprising the amino acid sequence as set forth in SEQ ID NO: 5;
wherein the second antigen-binding region capable of binding to human CD137 comprises a second VH region comprising an HCDR1 sequence comprising the amino acid sequence as set forth in SEQ ID NO: 64, an HCDR2 sequence comprising the amino acid sequence as set forth in SEQ ID NO: 65, and an HCDR3 sequence comprising the amino acid sequence as set forth in SEQ ID NO: 66, and a second VL region comprising a LCDR1 sequence comprising the amino acid sequence as set forth in SEQ ID NO: 67, a LCDR2 sequence comprising the amino acid sequence GAS, and a LCDR3 sequence comprising the amino acid sequence as set forth in SEQ ID NO: 68,
wherein in at least one of said first and second heavy chains one or more amino acids in the positions corresponding to positions L234, L235, D265, N297, and P331 in a human IgG1 heavy chain according to EU numbering, are not L, L, D, N, and P, respectively.

2. The multispecific antibody or fragment thereof of claim 1 , wherein the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain according to EU numbering are F, E, and A, respectively, in said first and second heavy chains.

3. The multispecific antibody or fragment thereof of claim 2 , wherein the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain according to EU numbering of both the first heavy chain and the second heavy chain are F, E, and A, respectively, and wherein (i) the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering of the first heavy chain is L, and the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering of the second heavy chain is R, or (ii) the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering of the first heavy chain is R, and the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering of the second heavy chain is L.

4. The multispecific antibody or fragment thereof of claim 1 , wherein said antibody is able to cross-link a first cell expressing human CD40 and a second cell expressing human CD137.

5. The multispecific antibody or fragment thereof of claim 1 , wherein said antibody is a bispecific antibody.

6. The multispecific antibody or fragment thereof of claim 1 ,
wherein (i) the amino acid in the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L in said first heavy chain, and the amino acid in the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R in said second heavy chain, or (ii) the amino acid in the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R in said first heavy chain, and the amino acid in the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L in said second heavy chain.

7. The multispecific antibody or fragment thereof according to claim 1 , wherein the first VH region comprises the amino acid sequence as set forth in SEQ ID NO:117.

8. The multispecific antibody or fragment thereof according to claim 1 , wherein the second VH region comprises the amino acid sequence as set forth in SEQ ID NO:123.

9. The multispecific antibody or fragment thereof according to claim 1 , wherein the first VL region comprises the amino acid sequence as set forth in SEQ ID NO:121.

10. The multispecific antibody or fragment thereof according to claim 1 , wherein the second VL region comprises the amino acid sequence as set forth in SEQ ID NO: 127.

11. A multispecific antibody or a fragment thereof comprising a first heavy chain and a first light chain comprising a first antigen-binding region capable of binding to human CD40 and a second heavy chain and a second light chain comprising a second antigen-binding region capable of binding to human CD137,
wherein the first antigen-binding region comprises a first heavy chain variable (VH) region comprising an HCDR1 sequence comprising the amino acid sequence as set forth in SEQ ID NO: 1, an HCDR2 sequence comprising the amino acid sequence as set forth in SEQ ID NO: 2, and an HCDR3 sequence comprising the amino acid sequence as set forth in SEQ ID NO: 3, and a first light chain variable (VL) region comprising a LCDR1 sequence comprising the amino acid sequence as set forth in SEQ ID NO: 4, a LCDR2 sequence comprising the amino acid sequence YTS, and a LCDR3 sequence comprising the amino acid sequence as set forth in SEQ ID NO: 5;
wherein the second antigen-binding region comprises a second VH region comprising an HCDR1 sequence comprising the amino acid sequence as set forth in SEQ ID NO: 64, an HCDR2 sequence comprising the amino acid sequence as set forth in SEQ ID NO: 65, and an HCDR3 sequence comprising the amino acid sequence as set forth in SEQ ID NO: 66, and a second VL region comprising a LCDR1 sequence comprising the amino acid sequence as set forth in SEQ ID NO: 67, a LCDR2 sequence comprising the amino acid sequence GAS, and a LCDR3 sequence comprising the amino acid sequence as set forth in SEQ ID NO: 68,
wherein the positions corresponding to positions L234, L235, and D265 in the human IgG1 heavy chain according to EU numbering are F, E, and A, respectively, in the first and second heavy chains.

12. The multispecific antibody or fragment thereof of claim 11 , wherein (i) the amino acid in the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L in said first heavy chain, and the amino acid in the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R in said second heavy chain, or (ii) the amino acid in the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R in said first heavy chain, and the amino acid in the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L in said second heavy chain.

13. The multispecific antibody or fragment thereof according to claim 11 , wherein the first VH region comprises the amino acid sequence as set forth in SEQ ID NO:117.

14. The multispecific antibody or fragment thereof according to claim 11 , wherein the second VH region comprises the amino acid sequence as set forth in SEQ ID NO:123.

15. The multispecific antibody or fragment thereof according to claim 11 , wherein the first VL region comprises the amino acid sequence as set forth in SEQ ID NO:121.

16. The multispecific antibody or fragment thereof according to claim 11 , wherein the second VL region comprises the amino acid sequence as set forth in SEQ ID NO: 127.

17. A multispeci

Assignees

• Genmab As
• BioNTech SE

Inventors

• Altintas Isil
• Satijn David
• Rademaker Rik
• Parren Paul
• Gieseke Friederike
• Sahin Ugur

Classifications

• C07K2317/21

  from primates, e.g. man · CPC title

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/53

  Hinge · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title